US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by CEL-SCI Corporation

< Previous 1 2 3 Next >
News headline image
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Reports Fiscal Third Quarter 2026 Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Announces Closing of Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Corporation Announces Pricing of Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Reports Fiscal Second Quarter 2026 Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Announces Closing of Public Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Corporation Announces Pricing of Public Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Reports Fiscal First Quarter 2026 Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Reports Fiscal 2025 Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Announces Closing of $10 Million Public Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Announces Pricing of $10 Million Public Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Announces Proposed Public Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Announces Closing of Public Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Announces Pricing of Public Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Announces Proposed Public Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Announces Combination of Common Stock
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
< Previous 1 2 3 Next >